Name: Duravyu (vorolanib intravitreal insert) in Wet age-related macular degeneration: Effects of other drugs on vorolanib intravitreal insert
Published: 2026-09-17T18:16:06-04:00

Product information and disease description Product description Product information Drug/Drug, drug/disease interactions

Effects of other drugs on vorolanib intravitreal insert

2 evidence topics · 2 sources

Protocol restrictions on prior and concomitant therapies (phase 2)

“Previous use of any systemic anti-VEGF agents or intraocular brolucizumab in the study eye.” (opens the source at this quote in a new tab)
“Use of oral corticosteroids (prednisone >10 mg/day or equivalent) within 30 days prior to the Screening Visit.” (opens the source at this quote in a new tab)
“Use of anti-mitotic or anti-metabolite therapy within 30 days or 5 elimination half-lives of the Screening Visit, whichever is longer.” (opens the source at this quote in a new tab)

Clinical drug interaction studies

No evidence found.

Concomitant atorvastatin withheld with oral vorolanib during transaminase elevation

“An asymptomatic 69-year-old woman receiving 200 mg daily had an ALT level 8.4 times the ULN and an AST level 2.9 times the ULN at month 2. X-82 and atorvastatin were withheld.” (opens the source at this quote in a new tab)
“By month 3, the ALT level was 1.6 times the ULN and the AST level 1.1 times the ULN, and she was rechallenged with 100 mg of X-82 daily.” (opens the source at this quote in a new tab)